Antitumour necrosis factor-α chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function

British Journal of Dermatology

Volumn 157, Issue 2, 2007, Pages 249-258

  Bedini, C ^a   Nasorri, F ^a   Girolomoni, G ^b   De Pita O ^a   Cavani, A ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Dendritic cells; Infliximab; Psoriasis; T lymphocytes; Tumour necrosis factor

Indexed keywords

CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; NICKEL; T6 ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL HOMING; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD45; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; PSORIASIS; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447506397     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07945.x     Document Type: Article

References (53)

1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004 113 : 1664 75.
2. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005 352 : 1899 912.
3. Bos JD, de Rie MA, Teunissen MB et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005 152 : 1098 107.
4. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004 199 : 731 6.
5. Baker BS, Griffiths CE, Lambert S et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987 116 : 503 10.
6. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000 192 : 681 94.
7. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 345 : 248 55.
8. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 349 : 2004 13.
9. Ovigne JM, Baker BS, Brown DW et al. Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma. Exp Dermatol 2001 10 : 168 74.
10. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999 113 : 752 9.
11. Ottaviani C, Nasorri F, Bedini C et al. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006 36 : 118 28.
12. Baker BS, Powles AV, Valdimarsson H et al. An altered response by psoriatic keratinocytes to gamma interferon. Scand J Immunol 1988 28 : 735 40.
13. Jackson M, Howie SE, Weller R et al. Psoriatic keratinocytes show reduced IRF-1 and STAT-1alpha activation in response to gamma-IFN. FASEB J 1999 13 : 495 502.
14. Schottelius AJ, Moldawer LL, Dinarello CA et al. Biology of tumor necrosis factor-alpha - implications for psoriasis. Exp Dermatol 2004 13 : 193 222.
15. Caron G, Delneste Y, Aubry JP et al. Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol 1999 29 : 3588 95.
16. Parry SL, Sebbag M, Feldmann M et al. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol 1997 158 : 3673 81.
17. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996 334 : 1717 25.
18. Watts AD, Hunt NH, Wanigasekara Y et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J 1999 18 : 2119 26.
19. Harashima S, Horiuchi T, Hatta N et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001 166 : 130 6.
20. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004 140 : 218 25.
21. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993 30 : 1443 53.
22. Goedkoop AY, Kraan MC, Teunissen MB et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004 63 : 769 73.
23. ten Hove T, van Montfrans C, Peppelenbosch MP et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002 50 : 206 11.
24. van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 124 : 1774 85.
25. Smeets TJ, Kraan MC, van Loon ME et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003 48 : 2155 62.
26. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002 46 : 886 91.
27. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 42.
28. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
29. Albanesi C, Scarponi C, Cavani A et al. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000 115 : 81 7.
30. Kim EY, Teh HS. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004 173 : 4500 9.
31. Kim EY, Priatel JJ, Teh SJ et al. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006 176 : 1026 35.
32. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 52 : 3403 12.
33. Bakleh M, Tleyjeh I, Matteson EL et al. Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol 2005 44 : 443 8.
34. Kohlmann WM, Urban W, Sterry W et al. Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: conditions for cloning T cells from psoriatic plaques. Exp Dermatol 2004 13 : 607 12.
35. Vissers WH, Arndtz CH, Muys L et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004 150 : 852 9.
36. Kristensen M, Chu CQ, Eedy DJ et al. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993 94 : 354 62.
37. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 51.
38. Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994 19 : 383 7.
39. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992 6 : 2591 9.
40. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999 162 : 494 502.
41. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004 279 : 32633 42.
42. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998 101 : 783 94.
43. Asadullah K, Docke WD, Ebeling M et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999 135 : 187 92.
44. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004 53 : 70 7.
45. Bieber T, Ring J, Braun-Falco O. Comparison of different methods for enumeration of Langerhans cells in vertical cryosections of human skin. Br J Dermatol 1988 118 : 385 92.
46. Jones JL, Berth-Jones J, Fletcher A et al. Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis. J Pathol 1994 174 : 77 82.
47. Gordon KB, Bonish BK, Patel T et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005 153 : 945 53.
48. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 102 : 19057 62.
49. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994 94 : 202 9.
50. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 199 : 125 30.
51. Ritter U, Meissner A, Ott J et al. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF. J Leukoc Biol 2003 74 : 216 22.
52. Abe K, Yarovinsky FO, Murakami T et al. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 2003 101 : 1477 83.
53. Cumberbatch M, Dearman RJ, Uribe-Luna S et al. Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000 100 : 21 8.